Patent application number | Description | Published |
20090053219 | METHODS AND COMPOSITIONS FOR INCREASING ALPHA-L-IDURONIDASE ACTIVITY IN THE CNS - Provided herein are methods and compositions for treating a subject suffering from a deficiency in α-L-Iduronidase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an α-L-Iduronidase. A therapeutically effective systemic dose is based on the specific CNS uptake characteristics of human insulin receptor antibody-α-L-Iduronidase fusion antibodies as described herein. | 02-26-2009 |
20090068206 | Delivery of pharmaceutical agents via the human insulin receptor - A humanized murine antibody is provided that binds to the human insulin receptor (HIR). The humanized murine antibody is suitable for use as a Trojan horse to deliver pharmaceutical agents to human organs and tissue that express the HIR. The humanized murine antibody is especially well suited for delivering neuropharmaceutical agents from the blood stream to the brain across the blood brain barrier (BBB). The humanized murine antibody may be genetically fused to the pharmaceutical agent or it may be linked to the pharmaceutical agent using an avidin-biotin conjugation system. | 03-12-2009 |
20090156498 | FUSION PROTEINS FOR DELIVERY OF GDNF TO THE CNS - The invention provides compositions, methods, and kits for increasing transport of GDNF across the blood brain barrier while allowing its activity to remain substantially intact. The GDNF is transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems. | 06-18-2009 |
20100077498 | COMPOSITIONS AND METHODS FOR BLOOD-BRAIN BARRIER DELIVERY IN THE MOUSE - The invention provides compositions and methods, for increasing transport of CNS-active agents across the blood brain barrier in a mouse, e.g., a mouse model of a human CNS condition, while allowing their activity once across the barrier to remain substantially intact. The CNS-active agents are transported across the blood brain barrier via the mouse transferrin receptor. In some embodiments the agents are therapeutic, diagnostic, or research agents. | 03-25-2010 |
20100098693 | COMPOSITIONS AND METHODS FOR BLOOD-BRAIN BARRIER DELIVERY OF ORGANOPHOSPHATASES - Provided herein are compositions and related methods for delivering an organophosphatase to the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a receptor expressed on the surface of the blood-brain barrier (BBB receptor) and an organophosphatase. In some embodiments, the compositions described herein are used to treat a subject suffering from or at high risk of exposure to an organophosphate (e.g., a nerve gas). | 04-22-2010 |
20100261647 | FUSION PROTEINS FOR DELIVERY OF ERYTHROPOIETIN TO THE CNS - The invention provides compositions, methods, and kits for increasing transport of a neurotrophin (e.g., erythropoietin (EPO)) across the blood brain barrier while allowing its activity to remain substantially intact. The neurotrophin (e.g., EPO) is transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems. | 10-14-2010 |
20100290985 | MACROMOLECULAR COMPOSITIONS THAT CROSS THE BLOOD-BRAIN BARRIER AND METHODS OF USE THEREOF - The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier. Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's disease. | 11-18-2010 |
20110110935 | Methods and Compositions for Increasing Iduronate 2-Sulfatase Activity in the CNS - Provided herein are methods and compositions for treating a subject suffering from a deficiency in iduronate 2-sulfatase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody that crosses the blood brain barrier (BBB) and an iduronate 2-sulfatase. | 05-12-2011 |
20120269807 | COMPOSITIONS AND METHODS FOR BLOOD-BRAIN BARRIER DELIVERY OF lgG-DECOY RECEPTOR FUSION PROTEINS - Provided herein are compositions and related methods for delivering an IgG-decoy receptor to the CNS. The methods include systemic administration of a bifunctional decoy receptor-BBB receptor antibody fusion antibody comprising a receptor extracellular domain (ECD) covalently linked to an antibody to a receptor expressed on the surface of the blood-brain barrier (BBB receptor). In some embodiments, the compositions described herein are administered to treat a subject suffering from a CNS condition. | 10-25-2012 |
20130142794 | Methods and Compositions for Increasing Arylsulfatase A Activity in the CNS - Provided herein are methods and compositions for treating a subject suffering from a deficiency in arylsulfatase A in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an arylsulfatase A. | 06-06-2013 |
20130287773 | Methods and Compositions for Increasing Arylsulfatase A Activity in the CNS - Provided herein are methods and compositions for treating a subject suffering from a deficiency in arylsulfatase A in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an arylsulfatase A. | 10-31-2013 |
20140193409 | FUSION PROTEINS FOR DELIVERY OF GDNF TO THE CNS - The invention provides compositions, methods, and kits for increasing transport of GDNF across the blood brain barrier while allowing its activity to remain substantially intact. The GDNF is transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems. | 07-10-2014 |
20140288273 | MACROMOLECULAR COMPOSITIONS THAT CROSS THE BLOOD-BRAIN BARRIER AND METHODS OF USE THEREOF - The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier. Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's disease. | 09-25-2014 |
20140294822 | METHODS AND COMPOSITIONS FOR INCREASING ARYLSULFATASE A ACTIVITY IN THE CNS - Provided herein are methods and compositions for treating a subject suffering from a deficiency in arylsulfatase A in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an arylsulfatase A. | 10-02-2014 |
20150023956 | METHODS AND COMPOSITIONS FOR INCREASING ENZYME ACTIVITY IN THE CNS - Provided herein are methods and compositions for treating a subject suffering from an enzyme deficiency in the central nervous system (CNS). The bifunctional fusion antibodies provided herein comprise an antibody to an endogenous blood brain barrier (BBB) receptor and an enzyme deficient in mucopolysaccharidosis III (MPS-III). The fusion antibodies provided herein comprise N-sulfoglucosamine sulfohydrolase (SGSH), alpha-N-acetylgulcosaminidase (NAGLU), heparin-alpha-glucosaminide N-acetyltransferase (HGSNAT), or N-acetylglucosamine-6-sulfatase (GNS). The methods of treating an enzyme deficiency in the CNS comprise systemic administration of a fusion antibody provided herein. | 01-22-2015 |
20150064184 | METHODS AND COMPOSITIONS FOR INCREASING ARYLSULFATASE A ACTIVITY IN THE CNS - Provided herein are methods and compositions for treating a subject suffering from a deficiency in arylsulfatase A in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an arylsulfatase A. | 03-05-2015 |